XML 20 R5.htm IDEA: XBRL DOCUMENT v3.25.2
Condensed Consolidated Statement of Stockholders’ Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2023   12,823,665    
Beginning balance at Dec. 31, 2023 $ 186,024 $ 0 $ 373,178 $ (187,154)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation expense 1,045   1,045  
Common stock issued upon exercise of stock options (in shares)   37,330    
Common stock issued upon exercise of stock options 629   629  
Net loss (16,921)     (16,921)
Ending balance (in shares) at Mar. 31, 2024   12,860,995    
Ending balance at Mar. 31, 2024 170,777 $ 0 374,852 (204,075)
Beginning balance (in shares) at Dec. 31, 2023   12,823,665    
Beginning balance at Dec. 31, 2023 186,024 $ 0 373,178 (187,154)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net loss (35,413)      
Ending balance (in shares) at Jun. 30, 2024   12,989,208    
Ending balance at Jun. 30, 2024 155,014 $ 0 377,581 (222,567)
Beginning balance (in shares) at Mar. 31, 2024   12,860,995    
Beginning balance at Mar. 31, 2024 170,777 $ 0 374,852 (204,075)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Shares issued upon the exercise of pre-funded warrants (in shares)   103,407    
Stock-based compensation expense 2,314   2,314  
Common stock issued upon exercise of stock options (in shares)   24,806    
Common stock issued upon exercise of stock options 415   415  
Net loss (18,492)     (18,492)
Ending balance (in shares) at Jun. 30, 2024   12,989,208    
Ending balance at Jun. 30, 2024 $ 155,014 $ 0 377,581 (222,567)
Beginning balance (in shares) at Dec. 31, 2024 14,854,725 14,854,725    
Beginning balance at Dec. 31, 2024 $ 310,375 $ 0 572,673 (262,298)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation expense 4,048   4,048  
Common stock issued upon exercise of stock options (in shares)   1,683    
Common stock issued upon exercise of stock options 19   19  
Common stock issued upon vesting of restricted stock units (in shares)   73,158    
Net loss (22,647)     (22,647)
Ending balance (in shares) at Mar. 31, 2025   14,929,566    
Ending balance at Mar. 31, 2025 $ 291,795 $ 0 576,740 (284,945)
Beginning balance (in shares) at Dec. 31, 2024 14,854,725 14,854,725    
Beginning balance at Dec. 31, 2024 $ 310,375 $ 0 572,673 (262,298)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Common stock issued upon exercise of stock options (in shares) 8,881      
Net loss $ (44,663)      
Ending balance (in shares) at Jun. 30, 2025 14,269,264 14,269,264    
Ending balance at Jun. 30, 2025 $ 273,255 $ 0 580,216 (306,961)
Beginning balance (in shares) at Mar. 31, 2025   14,929,566    
Beginning balance at Mar. 31, 2025 291,795 $ 0 576,740 (284,945)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation expense 3,408   3,408  
Exchange of common stock for pre-funded warrants (in shares)   (667,500)    
Common stock issued upon exercise of stock options (in shares)   7,198    
Common stock issued upon exercise of stock options 68   68  
Net loss $ (22,016)     (22,016)
Ending balance (in shares) at Jun. 30, 2025 14,269,264 14,269,264    
Ending balance at Jun. 30, 2025 $ 273,255 $ 0 $ 580,216 $ (306,961)